INBP Research | Milton Maxwell

INBP

Integrated BioPharma, Inc.

0.3100

+0.0000+0%

Dec 16, 4:00:00 PM EST

Upcoming Earnings

Report date

≈ -/-

Earnings Call Transcripts

This Quarter (Q1 '26)

No earnings call transcript available yet

Last Quarter (Q4 '25)

No earnings call transcript available

Key Stats

Market Cap

9.63M

P/E (TTM)

15.50

Basic EPS (TTM)

0.02

Dividend Yield

Recent Filings

8-K

Lease amended: space cut, rent up

2/18/26Feb 18, 2026

Integrated Biopharma's subsidiary Manhattan Drug Company signed a Fourth Amendment to its lease on February 17, 2026, trimming space from 116,175 to 110,095 square feet while hiking annual basic rent from $845,966 to $1,100,950, rising 3% yearly through January 31, 2029. Related-party deal with Vitamin Realty—owned by the estate of former chairman and Co-CEOs—locks in higher costs. Rent jumps sharply.

8-K

Revenue drops, losses emerge

2/11/26Feb 11, 2026

Integrated BioPharma reported Q2 revenue of $11.3M, down 10.3% from $12.6M last year, swinging to a $0.9M operating loss from $0.2M income. Six-month revenue fell 8.4% to $24.0M with a $0.7M operating loss; top two customers drove 89% of sales. Customer concentration deepened.

10-Q

Q2 FY2026 results

2/11/26Feb 11, 2026

Integrated BioPharma's Q2 FY2026 sales fell 10.6% y/y to $11.3M ended December 31, 2025, with Contract Manufacturing down 6.4% y/y to $10.9M on softer non-major customer volumes, while gross profit cratered to $29 from $1.2M as cost of sales hit 99.7%. Operating loss widened to $914 from income of $202, but net loss of $762 ($0.03/share) narrowed slightly from prior y/y on tax benefits; diluted shares held flat at 31.1M due to anti-dilution. Cash climbed to $5.3M on $1.9M operating cash flow (FCF $1.7M derived), bolstered by $4.5M revolver availability at SOFR+2.50% with no draws. Two customers drove 92% of sales. Customer concentration threatens stability.

8-K

Annual meeting results

12/1/25Dec 1, 2025

Integrated BioPharma stockholders overwhelmingly elected Eric Friedman as Class III director for a three-year term at the December 1, 2025 annual meeting, with 20.7 million for and just 183K withheld. They backed a three-year frequency for say-on-pay votes (20.4M for) and approved exec comp (20.8M for). Auditors CBIZ CPAs ratified. Continuity locked in.

8-K

Q3 revenue drops 6.6%

11/10/25Nov 10, 2025

Integrated BioPharma reported Q3 2025 revenue of $12.7 million, down 6.6% from $13.6 million in Q3 2024, with operating income slipping to $0.2 million from $0.5 million. Net income fell to $0.1 million or $0.00 per share. Top two customers drove 87% of revenue. Concentration risks loom large.

About

Integrated BioPharma, Inc., together with its subsidiaries, engages in the manufacturing, distributing, marketing and sale of vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. The company operates through two segments, Contract Manufacturing and Other Business Lines. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment provides warehousing and fulfilment services; and distributes raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.

CEO

Ms. Riva Kay Sheppard

IPO

10/30/1996

Website

https://ir.ibiopharma.com

Employees

153

Sector

Consumer Defensive

Industry

Packaged Foods